POLICY NAME Yupelri (revefenacin) POLICY # 2691P

Criteria

| Coverage Criteria | |
|-------------------|--|
| | Documented diagnosis of Chronic Obstructive Pulmonary Disease (COPD) |
| | Documented failure, severe intolerance, or contraindication to TWO long-acting muscarinic-receptor- antagonist (LAMA) inhalers such as Atrovent HFA, Tudorza Pressair, Spiriva Respimat, or Incruse Ellipta. |